Avid­i­ty’s $300M of­fer­ing; Rap­port rais­es $174M

Plus, news about Replim­mune, No­vo Nordisk and Bios­plice:

Avid­i­ty Bio­sciences is look­ing for $300M in stock sale: The RNA com­pa­ny is plan­ning a $300 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.